The State of Content Marketing for Pharma Companies in 2026

This is not a story about quality versus quantity, or about whether pharma is doing content marketing well. It is a story about whether pharma is doing it at all. For the overwhelming majority of companies in the dataset, the honest answer is no.

That matters because the rest of B2B has moved on. Buyers — including HCPs, payers, procurement, R&D leaders, and life sciences operators — now self-educate through search, AI assistants, peer content, and long-running newsletters before they ever speak to a salesperson. An industry whose public surface is brochure-ware is, by definition, absent from that journey.

The conspicuous gap is the missing middle: mid-sized commercial pharma, specialty pharma, and growth-stage biotech with commercial products. These companies have buyers, budgets, and competitive pressure — but rarely a content marketing function to match. It's where the upside is largest and the practice is thinnest.

The collapse at the bottom of the funnel is the clearest tell. Pricing pages, ROI calculators, side-by-side comparisons, structured case study libraries — the assets a buyer actually needs to make a decision — are functionally absent across the industry. Even among companies that publish regularly, the work stops well before the moment of conversion.

The post-purchase number is where pharma reveals its deepest structural blind spot. The near-total absence of adherence support, customer success content, account-expansion programming and lifecycle communications points to a discipline that still treats content marketing as an acquisition tool and has not yet recognised its application to retention, expansion and customer lifetime value.

This is a particularly costly omission in pharma. Adherence rates for chronic disease therapies routinely fall below 50% within the first year. The lifetime value of a successfully onboarded HCP, payer or institutional account dwarfs the cost of producing the content needed to support it. The roughly 1-in-30 allocation to post-purchase content is, in commercial terms, the largest discoverable inefficiency in the entire pharma content marketing dataset.

The other notable pattern is that, among companies that produce content at all, about a third are completely missing decision-stage content of any kind, and a quarter are completely missing consideration-stage content. These are not gaps in volume; they are absolute holes in the funnel. A buyer who reaches consideration on these sites has nowhere to go — they either bounce, search for a competitor, or in the AI search era get redirected to a third-party review platform that compares the company against its competitors without its input.

The 55% of content-active companies without funnel-segmented CTAs deploy what is best described as CTA passivity: a generic "Contact Us" or "Request a Demo" placed at the end of every blog post regardless of funnel position. This wastes the conversion opportunity the content has created. A reader who has just consumed a deep technical guide is asking a very different question than a reader who has just finished an introductory awareness piece, and a single CTA cannot answer both.

The implication is that the largest single conversion opportunity in pharma content marketing in 2026 is not producing more content. It is fixing the conversion architecture around the content that already exists. A content-active pharma company that audits and rebuilds its CTA strategy with funnel segmentation in mind can usually double the conversion rate of its existing traffic without producing a single new asset.

In-person and "humans-in-rooms" channels are the centre of gravity. Congresses, tradeshows, speaker programs and field marketing collectively appear in nearly half of all pharma marketing job posts. This is the discipline the industry hires for: getting branded and unbranded education in front of physicians at ASCO, ASH, ACC, AHA and equivalents; equipping field reps with detail aids and approved messaging; supporting territory-level activity. The pharma marketer's calendar is structured around the congress year, not around the content calendar.

Among digital channels, owned platforms outrank paid platforms by a wide margin. LinkedIn and email together appear in roughly one in five posts, while paid search, programmatic and paid social collectively appear in roughly one in eight. This is the inverse of consumer marketing's dependency on paid acquisition, and reflects a structural truth about regulated promotion: paid digital placements for branded pharma carry MLR submission requirements, fair-balance overhead and OPDP risk that makes broadcast media expensive and slow. Owned channels are operationally easier to govern.

The conspicuous absences are where the strategic opportunity lies. Content marketing as a named discipline appearing in only about 1 in 45 posts is not a sign that the industry is failing to keep up with B2B SaaS — it is a sign that the industry has structurally declined to embrace content marketing as a primary function. SEO at 1 in 20 means the foundational layer of any modern B2B demand engine is not being hired for at scale. Podcasts at zero and AI search at a handful are the clearest indicators of channels where pharma has effectively conceded share of voice to non-pharma sources.

What this channel picture means for content marketing strategy specifically is that pharma marketers operate inside a mix where content sits well below the centre of gravity. A content marketing investment in pharma is competing for attention and budget against a deeply entrenched congress-and-field model, and any strategy that does not understand and respect that model will struggle to get internal traction.

Regulatory fluency is the price of admission. Roughly 7 in 10 job posts mention either regulatory knowledge or compliance. The mentions are not abstract — posts reference MLR review, promotional review committees, OPDP, fair balance and pharmacovigilance reporting by name. A content marketer entering pharma from B2B SaaS or consumer marketing without working knowledge of MLR is functionally unhirable for senior roles. This raises a real talent barrier into pharma content marketing — and explains why the industry recruits so heavily from within itself, reinforcing the channel and tactical conservatism documented elsewhere in this report.

Payer-language fluency has joined HCP language as a required register. Payer and market access communications now narrowly outpace HCP and clinician engagement in job posts — a notable shift driven by Inflation Reduction Act negotiations in the US and tightening reimbursement scrutiny in Europe. Marketers are increasingly expected to speak HEOR language alongside the traditional clinical-message register. Content programs that ignore the payer audience are increasingly hiring against an outdated discipline.

Content strategy itself is hired for in only about 1 in 6 posts. Not zero — but well below where comparable B2B industries would land. Combined with the 1-in-45 hiring rate for content marketing as a named tactical discipline, the picture is one where content strategy exists as an aspiration in roughly a sixth of postings, but as a planned, named tactic in only a tiny fraction.

Patient engagement is hired for less than the industry's external rhetoric implies. Despite years of "patient-centric" positioning, patient engagement appears in only about 1 in 7 posts. This may reflect that patient work is being housed in separate patient services functions, or a real gap between rhetoric and operational priority. Either way, content programs aimed at patients are not the centre of gravity of pharma's marketing investment.

The composite implication is that pharma has, by deliberate hiring choices, built marketing functions optimised for orchestrating complex cross-functional programs and navigating regulatory constraints — but not optimised for the craft execution content marketing demands at scale. The execution gap is filled by external partners, which means the quality and consistency of pharma content varies more by who the company partners with than by the company's internal capability.

The more revealing statistic is the gap between the median and the average within each band. In the $1M–$10M band, for example, median traffic of about 110 visits sits alongside average traffic of nearly 1,000. That gap means a small number of high-performing companies are pulling the average up dramatically, while the typical company barely registers. The top performers in this cohort generate roughly 100× more traffic than their peers at the same revenue band.

This pattern is consistent across every revenue tier and tells us something important: SEO performance in pharma is not primarily a function of company size or revenue. It is a function of deliberate content strategy and investment. Companies that invest in SEO compound; companies that don't, don't — regardless of how much revenue they have.

When we examine the funnel distribution of pharma's organic keyword universe, the imbalance is severe.

The traffic distribution mirrors the keyword distribution almost exactly: about 97% of total organic traffic comes from TOFU keywords, with MOFU and BOFU each contributing under 2%. The average CPC for MOFU keywords is about 36% higher than for TOFU — telling us that the commercial intent on those middle and bottom keywords is real, but that pharma companies are not capturing it. The keywords with the highest commercial value to a buying decision represent a vanishingly small fraction of pharma's organic visibility.

The branded-vs-non-branded split adds another layer. Branded keywords represent roughly 1 in 8 of pharma's ranked keywords but drive about 4 in 10 of all organic traffic. For many pharma companies, the bulk of their visible organic traffic is people who already knew the company existed. Non-branded traffic — the audience-expansion lever — accounts for about 6 in 10 of total traffic, but that share is artificially inflated by a small group of companies with strong content programs. For the median pharma company, the non-branded share is dramatically lower.

The strategic implication is that pharma's SEO opportunity is not in TOFU. Pharma is already TOFU-heavy. The opportunity is in MOFU and BOFU — the comparison content, the alternative pages, the pricing-and-packaging content, the use-case pages — that almost no pharma company currently produces at scale. A pharma services company that publishes "best clinical trial management software" or "Veeva CRM alternative" or "clinical trial recruitment vendor comparison" is entering a space where the existing competitive set is, in many cases, third-party review platforms rather than pharma companies themselves. That is an unusually favourable competitive position.

The structural reasons are real. FDA guidance on prescription drug advertising (21 CFR Part 202) requires paid search ads for prescription drugs to include the drug's generic name, at least one approved indication, and a brief summary of risks. Fitting fair balance and risk disclosure into Google Search ad character limits is genuinely difficult, which deters many prescription-drug marketers from running paid search at all. Most pharma companies targeting HCPs invest instead in specialist HCP portal advertising (Epocrates, Doximity, Medscape) and conference programming, where the audience is verified and the channel is purpose-built for regulated promotion.

But the structural reasons explain only the prescription-drug part of the picture. They do not explain why pharma services companies, OTC manufacturers, diagnostics firms, clinical trial recruiters and biotech services vendors — none of which face the same regulatory constraints — show paid search adoption at the same low rates. There is no FDA reason that a CRO cannot run paid search on "clinical trial management software." There is no FDA reason that a diagnostics firm cannot bid on "blood test for X." The low adoption rate in these segments reflects a cultural reluctance to embrace performance marketing as a primary channel rather than a regulatory constraint.

Where pharma does run paid search, spend ranges roughly as follows.

For pharma companies running paid search, three dominant ad group strategies emerge.

The strategic implication for content marketing is direct. None of the leading content-active pharma companies use paid search to amplify content assets. A review of Google Ads Transparency Center data for the largest LinkedIn-following companies in the content-active cohort (Quanticate, AutoCruitment, LabVantage, DeciBio) found that 100% of observed active ads pointed to service pages and product landing pages — not to whitepapers, webinars, or blog posts.

This is a fundamental misalignment between content investment and paid media strategy. Companies that produce high-quality content but fail to amplify it through paid channels are leaving substantial top-of-funnel opportunity unrealised. The combination of low organic search competition (because most pharma sites are brochures) and the absence of paid content amplification means that a small, well-executed paid-content strategy in pharma can produce outsized returns.

A qualitative review of recent posts from the top LinkedIn followers in the content-active cohort reveals a clear and limiting pattern: LinkedIn is used primarily as a broadcast channel for content promotion rather than as a community-building or conversation-starting tool. Posts typically share links to blog articles, webinar registrations or event announcements, with limited use of native LinkedIn formats — carousels, polls, documents — that tend to generate higher organic reach. The companies that break this pattern stand out: Quanticate, in particular, uses LinkedIn to promote its QCast podcast series and to share short-form educational content about its AI-assisted biostatistics tools, building a multi-format content presence that combines long-form website content, short-form LinkedIn posts and audio content.

LinkedIn advertising in pharma clusters around three primary campaign archetypes.

The limit of LinkedIn-as-default is the same as the limit of any single-channel strategy. LinkedIn is genuinely effective for B2B pharma audiences — HCPs, payers, investors, advocacy organisations — but it is not a discovery channel for net-new audiences in the way that organic search and AI search are. A company that relies on LinkedIn as its primary content distribution mechanism is, in effect, repeatedly reaching the audience that already follows it. Audience expansion requires the other distribution channels that pharma has historically underinvested in.

Pharma company websites appear in roughly one-third of AI-generated answers for top-of-funnel informational queries, but appear in effectively zero of the AI-generated answers for consideration-stage and decision-stage queries. Three patterns explain the result.

Building presence on G2 and Capterra is, for pharma services companies, now a primary AI search optimisation activity. Converting PDF content to structured HTML with clear headings, tables and schema markup is a high-priority migration project for any pharma content team taking AI search seriously.

The opportunity inside this picture is also real. Pharma companies that publish structured, authoritative, non-promotional content on topics where government sources are limited can achieve AI search visibility that drives meaningfully qualified traffic. The competitive set for these topics is small and the bar is currently low.

The combined picture of AI search in pharma is asymmetric. The visibility risk is significant: a pharma company that scores well in traditional Google search may be invisible in ChatGPT or Perplexity for the same query. The visibility opportunity is also significant: the AI answer layer is far less saturated by pharma sources than the traditional search layer, and a deliberate AEO/GEO strategy can win categories where Google rankings are already a lost cause.

The hiring data confirms that this opportunity is not yet being taken seriously. AEO and AI-search optimisation appear in only about 1 in 200 pharma marketing job posts. The industry knows AI search exists but has not yet decided to hire against it. For first-mover companies, that delay is the window.

When we break MarTech adoption down by revenue band, the picture clarifies further. The single most important figure in this table is the CRM number.

This matters for content marketing specifically because the entire value chain of content marketing — from attribution to nurture to handoff to sales — runs through the CRM. A pharma company without a CRM cannot meaningfully track which content assets contribute to which deals, cannot nurture leads through differentiated content sequences, cannot segment audiences for personalised content delivery, and cannot connect content engagement to sales outcomes. The roughly 1-in-12 CRM adoption rate across pharma is the single largest infrastructure constraint on the industry's content marketing maturity.

Marketing automation adoption tracks CRM adoption closely, which is unsurprising — the two systems are usually adopted together. HubSpot leads the marketing automation category at about 10% adoption, with Marketo at 2–3%. Veeva CRM, the industry-specific life sciences platform, appears in under 2% of detected installations — a figure that will likely grow significantly as more biotechs cross into commercial stage and need life-sciences-specific CRM functionality.

The WordPress finding deserves a separate note. WordPress runs more than a third of pharma sites in the sample, including many large-cap companies. WordPress is highly flexible and well-supported by a large ecosystem, but it requires significant customisation, security hardening and governance to meet pharma's regulatory requirements (21 CFR Part 11 for electronic records, GDPR, HIPAA where applicable). The prevalence of WordPress suggests many pharma companies have prioritised cost and ease of deployment over enterprise-grade compliance infrastructure — a choice that may be sustainable for early-stage and biotech companies but creates real audit and governance risk for commercial-stage and large-cap pharma.

The strategic implication is that, for many pharma companies, the highest-leverage marketing investment in 2026 is not more content. It is the infrastructure that makes content work — a CRM, a marketing automation platform, a tag management strategy, and the basic analytics architecture to connect content engagement to commercial outcomes. Companies that try to scale content marketing without this foundation produce content that drifts away from the funnel rather than feeding it.

The two-thirds named-author rate is a meaningful improvement over the broader industry baseline, but the remaining one-third of content-active companies that publish under anonymous or generic bylines represent a substantial E-E-A-T deficit. In a sector where the credibility of the author is directly correlated with the perceived credibility of the content, anonymous authorship is a material competitive disadvantage — particularly in the AI search era, where engines actively evaluate author authority signals when deciding what to cite.

The most important and most underused E-E-A-T signal is original research. Only about 3 in 10 content-active pharma companies publish proprietary data, original surveys or novel analyses. This is the content type that generates the most backlinks, the most social shares, the most AI citations and the most lasting authority. Companies that invest in original research create content assets competitors cannot replicate, because the underlying data is unique to them.

The 21% rate for dedicated expert or team pages is a missed opportunity. A well-constructed experts page — listing credentials, publications and areas of expertise of key contributors — provides a persistent E-E-A-T signal that benefits every piece of content on the site, not just individual articles. Building this once pays dividends across every future content asset.

Both CytoSorbents and Nautilus Biotechnology signal an evolution from "content marketing" as a separate function toward content as an extension of scientific communication, which is likely the direction the industry will move over the next several years.

The newsletter signup rate is encouraging — a newsletter is the most durable owned-distribution mechanism available, immune to algorithm changes on third-party platforms, and a long-term asset that compounds in value over years. But the content repurposing rate at just over half indicates that even content-active pharma companies are leaving major reach on the table. A single long-form piece can be repurposed into a LinkedIn carousel, a YouTube explainer, a podcast episode, an email sequence, a webinar topic and a research note. The companies that operate this kind of repurposing flywheel — Quanticate is the standout example in the dataset — generate dramatically more reach per asset than companies that publish each asset once.

The off-site distribution gap is the larger structural problem. Press syndication and PR distribution appears in only about 1 in 4 content-active companies. Paid amplification of content assets appears in essentially zero. Off-site amplification through HCP-specialist platforms, through industry trade publications, through co-marketing with KOL networks, and through sponsorship of authoritative third-party content is conspicuously absent.

A pharma company that places content directly inside those consumption channels reaches the audience where they already are, rather than asking the audience to come find the content on the company's own domain. The companies that build distribution partnerships with specialist platforms compound reach far faster than the companies that rely on owned-channel publishing alone.

Where salary data is disclosed (about 1 in 4 posts), the gradient by seniority and company size is clear.

The size-of-company premium is significant: large and enterprise pharma pays roughly 60% more than mid-size pharma for the same level role. The small/emerging biotech pay competitiveness is also notable — small biotechs pay nearly as well as large pharma because they are competing for pre-launch commercial talent and willing to pay close-to-large-pharma rates to attract it.

The implication for content marketing budgets specifically is that the cost of senior in-house headcount is substantial, which is one of the reasons pharma runs so heavily on agency partnerships for execution. It is more cost-efficient to outsource tactical content production to specialist agencies than to build a junior internal team to do it.

For directional planning purposes, estimated annual marketing budgets by revenue range look roughly as follows.

These figures are directional and vary widely by therapeutic area, pipeline stage and commercial model. The allocation patterns across stages are more reliable than the absolute figures: early-stage R&D companies typically prioritise credibility-building through scientific communications and a strong digital presence; clinical-stage and growth companies shift toward CRM implementation and paid-media; commercial-stage companies invest heavily in MarTech integration and full multi-channel orchestration.

Channel-specific spend benchmarks for content-relevant categories cluster as follows.

The likely reason is regulatory. AI-generated promotional content faces MLR review and fair-balance scrutiny that AI-driven analytics does not. Pharma's AI adoption is, predictably, easier on the decisioning side (where AI augments existing analytics workflows) than on the content side (where AI outputs need to pass through approval processes that were not designed for AI-generated artefacts).

The directional implication is that pharma's AI adoption over the next two to three years will be analytical and decisioning first, generative-content second. Expect "AI for next-best-action," "AI for HCP targeting," and "AI-augmented segmentation" to appear as named skills before "GenAI content creation" or "prompt engineering for marketing." Companies that try to lead with content-generation AI before resolving the MLR review pipeline for AI outputs will face friction. Companies that lead with decisioning AI on top of their existing Veeva and analytics stacks will find an easier path — and the early adopters in that direction are already in market.

For content marketing teams specifically, the practical implication is that AI productivity gains will accrue first to the back-office of content production — research, briefing, drafting, summarisation, repurposing — and only later to the public-facing content itself. Teams that build internal AI-augmented workflows for non-promotional content (raw asset extraction from SME interviews, competitive analysis, first-draft briefing) will compound a real productivity advantage long before AI-generated promotional content is operationally viable.